Evidence map›Paper›PMID 37931781›Full record

ArticleMathematical biosciences2023

Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy.

Angela M Jarrett, Patrick N Song, Kirsten Reeves, Ernesto A B F Lima, Benjamin Larimer, Thomas E Yankeelov, Anna G Sorace

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mathematical biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Angela M JarrettOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, USA; Livestrong Cancer Institutes, The University of Texas at Austin, USA.
Patrick N SongDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama USA.
Kirsten ReevesDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama USA; Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, Alabama USA.
Ernesto A B F LimaOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, USA; Livestrong Cancer Institutes, The University of Texas at Austin, USA.
Benjamin LarimerDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama USA.
Thomas E YankeelovOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, USA; Livestrong Cancer Institutes, The University of Texas at Austin, USA; Departments of Biomedical Engineering, The University of Texas at Austin, USA; Diagnostic Medicine, The University of Texas at Austin, USA; Oncology, The University of Texas at Austin, USA; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. Electronic address: thomas.yankeelov@utexas.edu.
Anna G SoraceDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama USA; Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama USA. Electronic address: asorace@uabmc.edu.
University of Alabama at Birmingham · USLivestrong Foundation · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Site-Specific Immune Cell Activation Detection for Improving Individualized Cancer ImmunotherapyDP2CA261453 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LARIMER, BENJAMIN M · 2020 to 2020
$2.2M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
Mathematical modeling and molecular imaging to maximize response while minimizing toxicities from systemic therapies in preclinical models of breast cancerR01CA276540 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C, YANKEELOV, THOMAS E · 2023 to 2025
$1.4M
NCI NIH HHS DP2 CA261453NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA240589NCI NIH HHS R01 CA276540
6 · The paper itself

Abstract

Immunotherapies such as checkpoint blockade to PD1 and CTLA4 can have varied effects on individual tumors. To quantify the successes and failures of these therapeutics, we developed a stepwise mathematical modeling strategy and applied it to mouse models of colorectal and breast cancer that displayed a range of therapeutic responses. Using longitudinal tumor volume data, an exponential growth model was utilized to designate response groups for each tumor type. The exponential growth model was then extended to describe the dynamics of the quality of vasculature in the tumors via [

Indexed as

NeoplasmsAnimalsDisease Models, AnimalImmunotherapyMicePositron-Emission TomographyComputationalE0771FMISO-PETHypoxiaImagingImmune responseMC38

Identifiers

PMID37931781
PMCPMC10841996
OpenAlexW4388337036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.